查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1984880

全球流感疫苗市場：依疫苗類型、生產流程、給藥途徑、年齡層、通路及地區劃分－市場規模、產業動態、機會分析及預測（2026-2035 年）

Global Influenza Vaccine Market: By Type, By Process, Route of Administration, Age Group, Distribution Channel, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 312 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球流感疫苗市場正經歷快速轉型和顯著成長。預計到 2025 年，市場規模將達到約 107.7 億美元，到 2035 年將達到 307.7 億美元。這一增長意味著在 2026 年至 2035 年的預測期內，複合年增長率 (CAGR) 將達到 11.07%。推動市場擴張的主要因素包括全球季節性流感發病率的上升、人口老化等人口結構變化，以及各國政府為提高疫苗接種率和加強公共衛生防範所做的努力。

季節性流感爆發的頻率和嚴重程度不斷增加是市場成長的主要驅動因素之一。流感仍然是一項重大的公共衛生挑戰，每年感染數百萬人，導致高發病率和高死亡率，尤其是在老年人和慢性病患者等弱勢群體中。這項持續存在的威脅凸顯了採取有效預防措施的迫切性，並推動了對流感疫苗的穩定需求。

主要市場趨勢

流感疫苗市場的特點是主要參與者之間的激烈競爭，每家公司都試圖透過強大的研發活動、擴大產品組合和建立策略聯盟來鞏固其市場地位。領先企業認識到創新和多元化對於滿足不斷變化的市場需求和應對流感病毒株變異的挑戰至關重要。 賽諾菲在這個競爭激烈的市場中脫穎而出，成為主導力量，並透過將其疫苗產品組合轉向高價值產品來積極捍衛其市場領導地位。這項策略措施包括專注於高價值疫苗，例如高劑量製劑和佐劑製劑，尤其針對老年人等弱勢族群。 CSL正透過確立自身作為 "非雞蛋來源" 流感疫苗領先​​供應商的地位，開闢出一個獨特的細分市場。 CSL強調基於細胞培養的疫苗生產，為擔心雞蛋過敏或受雞蛋適應性病毒突變限制的醫護人員和患者提供了一種極具吸引力的傳統雞蛋來源疫苗替代方案。

葛蘭素史克（GSK）則採取了不同的策略，將重點轉向 "含佐劑疫苗" 策略，透過添加免疫增強物質來增強免疫反應。該策略針對對標準疫苗反應較弱的人群，例如老年人，旨在提高這些人群的疫苗整體有效性。

主要成長驅動因素

季節性流感發生率的上升是全球流感疫苗市場成長的關鍵驅動因素。每年，流感病毒都會導致廣泛的感染，造成頻繁且往往難以預測的疫情爆發，且疫情在不同地區的嚴重程度各不相同。這些季節性疫情對醫療系統造成沉重負擔，導致住院和就診人數增加，在嚴重病例中，死亡率也更高。疫情的反覆出現使得持續有效的預防措施變得尤為迫切，其中最重要的就是每年接種流感疫苗。

新機會與趨勢

流感疫苗市場正經歷重大變革，從傳統的雞蛋培養法轉向細胞培養和重組疫苗生產等更新、更先進的技術。這一轉變是一個充滿希望的趨勢，有望透過提高生產效率和疫苗效力來推動市場成長。雖然傳統的雞蛋培養法可靠且經濟高效，但它也存在一些局限性，例如生產週期長以及病毒適應性問題，這些問題可能會降低疫苗效力。相較之下，細胞培養和重組技術提供了創新的解決方案，可以應對許多此類挑戰，開啟流感疫苗研發的新時代。

優化障礙

由於嚴格的監管要求和疫苗研發的高昂成本，流感疫苗市場的成長面臨巨大的挑戰。其中最大的障礙之一是漫長的研發週期。通常，從初步研究到獲得市場批准需要 10 到 15 年的時間。如此漫長的過程反映了疫苗研發的複雜性，其中包括多階段臨床試驗、嚴格的安全性和有效性測試以及全面的生產驗證。這種延誤不僅減緩了創新疫苗的上市速度，也增加了製造商的財務風險，因為他們必須投入大量資源多年才能獲得投資回報。

目錄

第一章：研究架構

  • 研究目標
  • 產品概述
  • 市場區隔

第二章：研究方法

  • 質性研究
    • 一手和二手資料
  • 量化研究
    • 一手和二手資料
  • 主要調查受訪者分佈：依地區劃分
  • 本研究的假設
  • 市場規模估算
  • 數據三角測量

第三章：摘要整理：全球流感疫苗市場

第四章：全球流感疫苗市場概述

  • 產業價值鏈分析
    • 原料供應商
    • 製造商
    • 經銷商
    • 終端用戶
  • 行業展望
    • 65歲以上族群季節性流感呼吸道死亡率
    • 受影響最嚴重國家的國家流感中心
  • PESTLE分析
  • 波特五力分析
    • 供應商議價能力
    • 買方議價能力
    • 替代品威脅
    • 新進入者威脅
    • 競爭強度
  • 市場動態與趨勢
    • 成長驅動因素
    • 挑戰
    • 關鍵因素趨勢
  • 市場成長與展望
    • 市場收入估計與預測（2020-2035 年）
    • 市場銷售估算與預測（百萬劑）（2020-2035 年）
    • 價格趨勢分析
  • 競爭格局概述
    • 市場集中度
    • 公司佔有率分析（價值，%），2025 年
    • 競爭格局圖
  • 實務見解（分析師建議）

第五章 全球流感疫苗市場分析：依疫苗類型劃分

  • 主要見解
  • 市場規模與預測：2020-2035 年（百萬美元，百萬劑）
    • 滅活​​疫苗流感疫苗 (IIV)
    • 減毒活流感疫苗 (LAIV)

第六章 全球流感疫苗市場分析：依生產流程劃分

  • 主要見解
  • 市場規模與預測：2020–2035 年（百萬美元，百萬劑）
    • 雞蛋來源
    • 細胞培養
    • 重組

第七章 全球流感疫苗市場分析：依給藥途徑劃分

  • 主要見解
  • 市場規模與預測：2020–2035 年（百萬美元，百萬劑）劑量）
    • 注射劑
    • 鼻腔噴劑

第八章 全球流感疫苗市場分析：依年齡組別劃分

  • 主要見解
  • 市場規模與預測：2020–2035 年（百萬美元，百萬劑）
    • 兒童
    • 成人

第九章 全球流感疫苗市場分析：依通路劃分

  • 主要見解
  • 市場規模與預測：2020–2035 年（百萬美元，百萬劑）
    • 醫院和藥房
    • 政府供應商
    • 其他

第十章 全球流感疫苗市場分析：依地區劃分

  • 主要見解
  • 市場規模與預測：2020–2035 年（百萬美元，百萬劑）
    • 北美
    • 歐洲
    • 亞太地區
    • 中東和非洲
    • 南美

第 11 章 北美流感疫苗市場分析

第 12 章 歐洲流感疫苗市場分析

第 13 章 亞太地區流感疫苗市場分析

第 14 章 中東與非洲流感疫苗市場分析

第 15 章 南美洲流感疫苗市場分析

第16章 企業簡介

  • Abbott Laboratories
  • AstraZeneca
  • Emergent BioSolutions Inc
  • Emergex Vaccines Holding Limited
  • GSK plc
  • Merck &Co., Inc.
  • OSIVAX
  • Pfizer Inc.
  • Sanofi SA
  • CSL Limited
  • Sinovac Biotech Ltd.
  • SK bioscience Co., Ltd.
  • Viatris Inc.
  • Other Prominent Players

第17章 附錄

簡介目錄
Product Code: AA0124744

The global influenza vaccine market is experiencing a period of rapid transformation and substantial growth. Valued at approximately US$ 10.77 billion in 2025, the market is projected to expand significantly, reaching an estimated valuation of US$ 30.77 billion by 2035. This growth corresponds to a robust compound annual growth rate (CAGR) of 11.07% over the forecast period from 2026 to 2035. Several key factors are driving this expansion, including the increasing incidence of seasonal influenza cases worldwide, demographic shifts characterized by a growing aging population, and enhanced government initiatives aimed at bolstering vaccination coverage and public health preparedness.

One of the primary contributors to the market's growth is the rising frequency and severity of seasonal flu outbreaks. Influenza continues to pose a major public health challenge, with millions affected annually, leading to substantial morbidity and mortality, especially among vulnerable groups such as the elderly and individuals with chronic health conditions. This ongoing threat underscores the critical need for effective preventive measures, fueling consistent demand for influenza vaccines.

Noteworthy Market Developments

The influenza vaccine market is characterized by intense competition among major players, each striving to strengthen its position through robust research and development efforts, portfolio expansion, and strategic collaborations. Leading companies recognize the importance of innovation and diversification to meet evolving market demands and to address the challenges posed by changing influenza virus strains.

Sanofi stands out as a dominant force in this competitive landscape, aggressively defending its market leadership by transitioning its vaccine portfolio toward premium products. This strategic move involves focusing on high-value vaccines such as high-dose and adjuvanted formulations, which cater especially to vulnerable populations like seniors. CSL has carved out a distinctive niche by positioning itself as the leading provider of "Non-Egg" influenza vaccines. By emphasizing cell-based vaccine production, CSL offers an alternative to traditional egg-based vaccines that appeals to healthcare providers and patients concerned about egg allergies or the limitations associated with egg-adapted viral mutations.

GlaxoSmithKline (GSK) has adopted a different approach by pivoting toward an adjuvanted vaccine strategy, which involves enhancing immune responses through the inclusion of immune-boosting substances. This strategy targets populations that may have weaker responses to standard vaccines, such as older adults, aiming to improve overall vaccine efficacy in these groups.

Core Growth Drivers

The rising incidence of seasonal influenza is a significant factor fueling the growth of the influenza vaccine market worldwide. Each year, influenza viruses cause widespread illness, leading to frequent and often unpredictable outbreaks that vary in severity across different regions. These seasonal epidemics place a considerable burden on healthcare systems, resulting in increased hospitalizations, medical consultations, and, in severe cases, mortality. The recurring nature of these outbreaks creates a continuous and urgent need for effective preventative measures, chief among them being annual influenza vaccinations.

Emerging Opportunity Trends

The influenza vaccine market is undergoing a significant transformation as it shifts from traditional egg-based manufacturing methods to newer, more advanced technologies such as cell-based and recombinant vaccine production. This transition represents a promising trend that is expected to drive market growth by enhancing both production efficiency and vaccine effectiveness. Traditional egg-based methods, while reliable and cost-effective, present certain limitations, including longer production timelines and potential issues with virus adaptation that can reduce vaccine efficacy. In contrast, cell-based and recombinant technologies offer innovative solutions that address many of these challenges, heralding a new era in influenza vaccine development.

Barriers to Optimization

The growth of the influenza vaccine market faces significant challenges due to stringent regulatory requirements and the high costs associated with vaccine development. One of the most critical barriers is the lengthy development timeline, which typically spans 10 to 15 years from initial research to market approval. This extended period reflects the complexity of vaccine development, which involves multiple phases of clinical trials, rigorous safety and efficacy testing, and comprehensive manufacturing validation. Such protracted timelines not only delay the introduction of innovative vaccines but also increase the financial risks for manufacturers, who must invest substantial resources over many years before seeing any return.

Detailed Market Segmentation

By Vaccine Type, the Inactivated Influenza Vaccine (IIV) segment overwhelmingly dominates the influenza vaccine market, commanding an impressive 89.60% share. This substantial market presence is largely rooted in the vaccine's well-established safety profile and its widespread acceptance as the standard of care across nearly all demographic groups. IIVs have long been trusted by healthcare professionals and patients alike, making them the go-to choice for influenza immunization worldwide. Their broad applicability, from children to elderly adults, has solidified their position as the cornerstone of influenza prevention strategies.

By Process, the egg-based process continues to hold a significant position in the influenza vaccine market, capturing a substantial 46.28% share according to the latest data. This manufacturing method remains the cornerstone of global vaccine production, primarily due to its cost-effectiveness and scalability. Despite advances in alternative production technologies, egg-based vaccine manufacturing has proven to be a reliable and practical solution, especially when it comes to meeting the immense annual global demand for influenza vaccines.

By Route of Administration, the injectable route remains the predominant method of administration in the influenza vaccine market, commanding a substantial 71.03% share. This dominance is largely attributed to its compatibility with the most widely used vaccine types-primarily the inactivated influenza vaccines (IIV) and recombinant influenza vaccines (RIV). These vaccine formulations are designed for intramuscular or subcutaneous injection, which remains the standard and most trusted approach for delivering influenza immunizations across diverse patient populations.

By Age Group, adults represent the largest consumer group within the influenza vaccine market, commanding an impressive 78.25% share of the overall market. This dominance is a critical factor in understanding the profitability dynamics within the industry. The adult demographic's substantial market share highlights not only the volume of vaccines administered but also the economic significance of this segment for manufacturers and healthcare providers. Unlike other groups, adults-particularly older adults-are the primary drivers of revenue growth and market value, making them the focal point for strategic targeting and product development.

Segment Breakdown

By Type

  • Inactivated influenza vaccine (IIV)
  • Quadrivalent
  • Trivalent
  • Live-attenuated influenza vaccine (LAIV)

By Process

  • Egg Based
  • Cell Culture-Based
  • Recombinant

By Route of Administration

  • Injectable
  • Intra-nasal

By Age Group

  • Pediatric
  • Adult

By Distribution Channel

  • Hospitals & Pharmacies
  • Government Suppliers
  • Others

By Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa (MEA)
  • South America

Geography Breakdown

  • North America stands out as the primary value hub in the global influenza vaccine market, with the United States and Canada representing the highest value region worldwide despite not having the largest population. This distinction is largely due to the unique characteristics of the US healthcare system, particularly its "Open Market" model. Unlike many countries where vaccine pricing is tightly regulated or capped by single-payer government tenders, the US allows for more flexible pricing structures. This open market environment enables manufacturers to introduce and widely distribute premium influenza vaccines.
  • Another critical factor underpinning North America's leadership in this sector is the highly optimized supply chain that supports vaccine distribution. The region benefits from a robust and efficient retail pharmacy infrastructure, with major chains such as CVS and Walgreens playing pivotal roles as primary points of care for influenza vaccination. These pharmacies provide convenient, accessible locations for patients to receive their vaccines without the need for a doctor's appointment, facilitating higher vaccination rates and improving public health outcomes.

Leading Market Participants

  • Abbott Laboratories
  • AstraZeneca
  • Emergent BioSolutions Inc
  • Emergex Vaccines Holding Limited
  • GSK plc
  • Merck & Co., Inc.
  • OSIVAX
  • Pfizer Inc.
  • Sanofi SA
  • CSL Limited
  • Sinovac Biotech Ltd.
  • SK Bioscience Co., Ltd.
  • Viatris Inc.
  • Other Prominent Players

Table of Content

Chapter 1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

Chapter 2. Research Methodology

  • 2.1. Qualitative Research
    • 2.1.1. Primary & Secondary Sources
  • 2.2. Quantitative Research
    • 2.2.1. Primary & Secondary Sources
  • 2.3. Breakdown of Primary Research Respondents, By Region
  • 2.4. Assumption for the Study
  • 2.5. Market Size Estimation
  • 2.6. Data Triangulation

Chapter 3. Executive Summary: Global Influenza Vaccine Market

Chapter 4. Global Influenza Vaccine Market Overview

  • 4.1. Industry Value Chain Analysis
    • 4.1.1. Material Provider
    • 4.1.2. Manufacturer
    • 4.1.3. Distributor
    • 4.1.4. End User
  • 4.2. Industry Outlook
    • 4.2.1. Respiratory mortality rate from seasonal influenza in the over-65's
    • 4.2.2. National Influenza Centers in Most Affected Countries
  • 4.3. PESTLE Analysis
  • 4.4. Porter's Five Forces Analysis
    • 4.4.1. Bargaining Power of Suppliers
    • 4.4.2. Bargaining Power of Buyers
    • 4.4.3. Threat of Substitutes
    • 4.4.4. Threat of New Entrants
    • 4.4.5. Degree of Competition
  • 4.5. Market Dynamics and Trends
    • 4.5.1. Growth Drivers
    • 4.5.2. Challenges
    • 4.5.3. Key Trends
  • 4.6. Market Growth and Outlook
    • 4.6.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
    • 4.6.2. Market Volume Estimates and Forecast (Mn Doses), 2020-2035
    • 4.6.3. Price Trend Analysis
  • 4.7. Competition Dashboard
    • 4.7.1. Market Concentration Rate
    • 4.7.2. Company Market Share Analysis (Value %), 2025
    • 4.7.3. Competitor Mapping
  • 4.8. Actionable Insights (Analyst's Recommendations)

Chapter 5. Global Influenza Vaccine Market Analysis, By Vaccine Type

  • 5.1. Key Insights
  • 5.2. Market Size and Forecast, 2020-2035 (US$ Mn & Mn Doses)
    • 5.2.1. Inactivated influenza vaccine (IIV)
      • 5.2.1.1. Quadrivalent
      • 5.2.1.2. Trivalent
    • 5.2.2. Live-attenuated influenza vaccine (LAIV)

Chapter 6. Global Influenza Vaccine Market Analysis, By Process

  • 6.1. Key Insights
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn & Mn Doses)
    • 6.2.1. Egg Based
    • 6.2.2. Cell Culture-Based
    • 6.2.3. Recombinant

Chapter 7. Global Influenza Vaccine Market Analysis, By Route of Administration

  • 7.1. Key Insights
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn & Mn Doses)
    • 7.2.1. Injectable
    • 7.2.2. Intra-Nasal

Chapter 8. Global Influenza Vaccine Market Analysis, By Age Group

  • 8.1. Key Insights
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn & Mn Doses)
    • 8.2.1. Paediatric
    • 8.2.2. Adult

Chapter 9. Global Influenza Vaccine Market Analysis, By Distribution Channel

  • 9.1. Key Insights
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn & Mn Doses)
    • 9.2.1. Hospitals & Pharmacies
    • 9.2.2. Government Suppliers
    • 9.2.3. Others

Chapter 10. Global Influenza Vaccine Market Analysis, By Region

  • 10.1. Key Insights
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn & Mn Doses)
    • 10.2.1. North America
      • 10.2.1.1. The U.S.
      • 10.2.1.2. Canada
      • 10.2.1.3. Mexico
    • 10.2.2. Europe
      • 10.2.2.1. Western Europe
        • 10.2.2.1.1. The UK
        • 10.2.2.1.2. Germany
        • 10.2.2.1.3. France
        • 10.2.2.1.4. Italy
        • 10.2.2.1.5. Spain
        • 10.2.2.1.6. Rest of Western Europe
      • 10.2.2.2. Eastern Europe
        • 10.2.2.2.1. Poland
        • 10.2.2.2.2. Russia
        • 10.2.2.2.3. Rest of Eastern Europe
    • 10.2.3. Asia Pacific
      • 10.2.3.1. China
      • 10.2.3.2. India
      • 10.2.3.3. Japan
      • 10.2.3.4. South Korea
      • 10.2.3.5. Australia & New Zealand
      • 10.2.3.6. ASEAN
      • 10.2.3.7. Rest of Asia Pacific
    • 10.2.4. Middle East & Africa
      • 10.2.4.1. UAE
      • 10.2.4.2. Saudi Arabia
      • 10.2.4.3. South Africa
      • 10.2.4.4. Rest of MEA
    • 10.2.5. South America
      • 10.2.5.1. Argentina
      • 10.2.5.2. Brazil
      • 10.2.5.3. Rest of South America

Chapter 11. North America Influenza Vaccine Market Analysis

  • 11.1. Key Insights
  • 11.2. Market Size and Forecast, 2020-2035 (US$ Mn & Mn Doses)
    • 11.2.1. By Vaccine Type
    • 11.2.2. By Process
    • 11.2.3. By Route of Administration
    • 11.2.4. By Age Group
    • 11.2.5. By Distribution Channel
    • 11.2.6. By Country

Chapter 12. Europe Influenza Vaccine Market Analysis

  • 12.1. Key Insights
  • 12.2. Market Size and Forecast, 2020-2035 (US$ Mn & Mn Doses)
    • 12.2.1. By Vaccine Type
    • 12.2.2. By Process
    • 12.2.3. By Route of Administration
    • 12.2.4. By Age Group
    • 12.2.5. By Distribution Channel
    • 12.2.6. By Country

Chapter 13. Asia Pacific Influenza Vaccine Market Analysis

  • 13.1. Key Insights
  • 13.2. Market Size and Forecast, 2020-2035 (US$ Mn & Mn Doses)
    • 13.2.1. By Vaccine Type
    • 13.2.2. By Process
    • 13.2.3. By Route of Administration
    • 13.2.4. By Age Group
    • 13.2.5. By Distribution Channel
    • 13.2.6. By Country

Chapter 14. Middle East & Africa Influenza Vaccine Market Analysis

  • 14.1. Key Insights
  • 14.2. Market Size and Forecast, 2020-2035 (US$ Mn & Mn Doses)
    • 14.2.1. By Vaccine Type
    • 14.2.2. By Process
    • 14.2.3. By Route of Administration
    • 14.2.4. By Age Group
    • 14.2.5. By Distribution Channel
    • 14.2.6. By Country

Chapter 15. South America Influenza Vaccine Market Analysis

  • 15.1. Key Insights
  • 15.2. Market Size and Forecast, 2020-2035 (US$ Mn & Mn Doses)
    • 15.2.1. By Vaccine Type
    • 15.2.2. By Process
    • 15.2.3. By Route of Administration
    • 15.2.4. By Age Group
    • 15.2.5. By Distribution Channel
    • 15.2.6. By Country

Chapter 16. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 16.1. Abbott Laboratories
  • 16.2. AstraZeneca
  • 16.3. Emergent BioSolutions Inc
  • 16.4. Emergex Vaccines Holding Limited
  • 16.5. GSK plc
  • 16.6. Merck & Co., Inc.
  • 16.7. OSIVAX
  • 16.8. Pfizer Inc.
  • 16.9. Sanofi SA
  • 16.10. CSL Limited
  • 16.11. Sinovac Biotech Ltd.
  • 16.12. SK bioscience Co., Ltd.
  • 16.13. Viatris Inc.
  • 16.14. Other Prominent Players

Chapter 17. Annexure

  • 17.1. List of Secondary Sources
  • 17.2. Key Country Markets - Macro Economic Outlook/ Indicators